Angela di Leo from the Hospital of Prato, Italy, presented results from the large Phase III CONFIRM trial of the synthetic oestrogen receptor antagonist fulvestrant in postmenopausal women with advanced, hormone receptor positive breast cancer. This evidence concerns the gene NR4A1 and breast cancer.